Compare SPT & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SPT | CMPX |
|---|---|---|
| Founded | 2010 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 485.7M | 408.8M |
| IPO Year | 2019 | 2020 |
| Metric | SPT | CMPX |
|---|---|---|
| Price | $8.44 | $1.91 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 9 |
| Target Price | $11.75 | ★ $14.57 |
| AVG Volume (30 Days) | 925.9K | ★ 2.3M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 32.11 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $457,547,000.00 | N/A |
| Revenue This Year | $8.86 | N/A |
| Revenue Next Year | $8.04 | $934.41 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 12.72 | N/A |
| 52 Week Low | $4.92 | $1.61 |
| 52 Week High | $16.03 | $6.88 |
| Indicator | SPT | CMPX |
|---|---|---|
| Relative Strength Index (RSI) | 55.28 | 34.71 |
| Support Level | $7.47 | $1.88 |
| Resistance Level | $9.12 | $2.02 |
| Average True Range (ATR) | 0.48 | 0.10 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 60.10 | 10.20 |
Sprout Social Inc develops a cloud software that brings together social messaging, data and workflows in a unified system of record, intelligence, and action. It has a centralized, secure and powerful platform that can scale horizontally across an organization to drive maximum business value. The firm generates majority revenue from software subscriptions. Geographically, the company operates in Americas, EMEA, and Asia Pacific, of which it derives maximum revenue from Americas.
Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to target the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-A, Bispecific, and CTX-8371.